Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with plaque-type psoriasis diagnosed at least 6 months prior and covering at least 10% of total body surface areas~* Have psoriasis area-and-severity index score of \>=12~* Patients who are considered by treating dermatologist to be a candidate for phototherapy or systemic treatment of psoriasis~* Have no history of latent or active TB~Exclusion Criteria:~* Currently have nonplaque forms of psoriasis or drug-induced psoriasis~* Have any therapeutic agent targeted at reducing IL-12 or IL-23~* Have had a BCG vaccination within the previous 12 months~* Have a history of chronic or recurrent infectious disease or who have or have had a serious infection requiring hospitalization or intravenous antibiotics within the previous 2 months~* Have or ever have had a nontuberculous mycobacterial infection or opportunistic infection~* Patients known to be infected with human immunodeficiency virus, hepatitis B, or hepatitis C~* Have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease~* Patients with a malignancy or who have a history of malignancy (with the exception of certain skin cancers and pre-invasive cervical cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ustekinumab 45 mg (Type: EXPERIMENTAL): Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.
- ustekinumab 90 mg (Type: EXPERIMENTAL): Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.
- Placebo (Type: PLACEBO_COMPARATOR): Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.

Based on this trial design, predict the completion outcome and termination type (if applicable).